Ontogenic loss of brown adipose tissue sensitivity to beta-adrenergic stimulation in the ovine.
In ruminants and other large animals, expression of uncoupling protein-1 (UCP1) in brown adipose tissue (BAT) is confined to the perinatal period when it plays a key role in nonshivering thermogenesis. This study determined whether loss of expression of the BAT phenotype was due to reduced response to a beta-agonist, isoprenaline, and expression of the peroxisome proliferator-activated receptor (PPAR) family [PPARalpha, PPARgamma, PPAR coactivator 1alpha (PGC-1alpha)], which regulates UCP1 gene expression. Perirenal adipose tissue (PAT) was sampled from ovine fetuses, newborn lambs, and lambs on d 1, 5, 7, and 21 of life. UCP1 mRNA and protein in PAT increased from d 123 of fetal life to reach a maximum at birth followed by a rapid decrease over the first 5 d of life. Expression of the coactivator, PGC-1alpha and PPAR alpha, peaked between fetal day 123 and birth, and then declined to undetectable levels in the first days of life. In vivo administration of isoprenaline was able to induce expression of UCP1, PGC-1alpha, and PPARalpha in BAT up to 5 d of age but thereafter was ineffective. In vitro addition of beta-receptor, PPARalpha, and PPARgamma agonists were unable to overcome the suppression of UCP1, PPARalpha, and PPARgamma expression observed in differentiated adipocytes prepared from 30-d-old compared with 1-d-old lambs. These data are consistent with a model in which postnatal loss of UCP1 expression and beta-adrenergic induction of the brown adipocyte phenotype is due to loss of expression of PGC-1alpha and PPARalpha.
Lomax
Michael A
MA
Division of Biomedical Science, Imperial College, Ashford, Kent TN25 5AH, UK. m.lomax@imperial.ac.uk
Sadiq
Fouzia
F
Karamanlidis
Georgios
G
Karamitri
Angeliki
A
Trayhurn
Paul
P
Hazlerigg
David G
DG
D017667:Adipocytes / Q000502:physiology; D002001:Adipose Tissue, Brown / Q000187:drug effects / Q000254:growth & development / Q000502:physiology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001833:Body Temperature Regulation / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects / Q000502:physiology; D007473:Ion Channels / Q000235:genetics; D007545:Isoproterenol / Q000494:pharmacology*; D008297:Male; D024101:Mitochondrial Proteins / Q000235:genetics; D047493:PPAR alpha / Q000819:agonists / Q000235:genetics; D047495:PPAR gamma / Q000819:agonists / Q000235:genetics; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D012756:Sheep; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism; D000071256:Uncoupling Protein 1
D000318:Adrenergic beta-Agonists; D007473:Ion Channels; D024101:Mitochondrial Proteins; D047493:PPAR alpha; D047495:PPAR gamma; D012333:RNA, Messenger; D011943:Receptors, Adrenergic, beta; D015534:Trans-Activators; D000071256:Uncoupling Protein 1; D007545:Isoproterenol